Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
NOURIANZ (istradefylline) is an oral tablet approved by the FDA in August 2019 for Parkinson's Disease and related movement disorders including apathy, tremor, and cognitive impairment. The mechanism of action and pharmacologic class are not specified in available data. It represents a non-biologic new drug application (NDA) addressing unmet needs in motor and non-motor symptoms of Parkinson's Disease.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Istradefylline Effect Protocol on Parkinson's Disease Tremor
Effect of Istradefylline Treatment on Behavioral Measures of Apathy in Parkinson's Disease.
Istradefylline for Parkinson Disease With Cognitive Impairment
A Study to Evaluate Abuse Potential of Istradefylline
Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
Worked on NOURIANZ at Inpharmus? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in ~2 years — expect lifecycle management and generic defense hiring
NOURIANZ currently has zero linked open positions, indicating minimal active recruitment at this stage of the product lifecycle. As the product approaches LOE, career opportunities would likely concentrate in generic preparation, supply chain, and managed care roles rather than brand-building functions. Skills in Parkinson's Disease patient populations, neurology key opinion leader relationships, and payer negotiation would be valuable for roles supporting this product through its lifecycle transition.